Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Dale Reynolds

Ophthalmology Sartell, MN Medical Doctor

NPI 1578531364 CMS profile 1148553

2330 Troop Dr, Suite 104, Sartell, MN 56377

Open in the dashboard

General payments

$147

4 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dale Reynolds of Sartell, MN is reported in the CMS Open Payments database as having received $147 across 4 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 15th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $108 2
2024 General $22 1
2020 General $18 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dale Reynolds
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Dale Reynolds were reported at $108. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Dale Reynolds Ophthalmology median Middle half National median
2019 $0 $258 $104–$655 $163
2020 $18 $126 $45–$321 $114
2021 $0 $205 $76–$534 $132
2022 $0 $266 $100–$678 $149
2023 $0 $308 $117–$745 $160
2024 $22 $340 $127–$846 $164
2025 $108 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Integra LifeSciences Corporation $108 2 payments
  2. Pacira Pharmaceuticals Incorporated $22 1 payment
  3. Regeneron Healthcare Solutions, Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $147 4 payments
Products named General payments · program years 2020–2025
  1. Integra Recon-Skin And Wound $108 2 payments
  2. Integra Recon-Skin And Wound $108 2 payments
  3. INTEGRA DERMAL REGENERATION TEMPLATE $108 2 payments
  4. OMNIGRAFT $108 2 payments
  5. SURGIMEND $108 2 payments
  6. Exparel $22 1 payment
  7. EYLEA $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,584

Median for Ophthalmology: 891

Drug cost

$37,660

Median for Ophthalmology: $68,233

Branded share of claims

37.4%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 559 $10,369
Prednisolone Acetate Generic 204 $9,566
Brimonidine Tartrate Generic 192 $4,068
Ketorolac Tromethamine Generic 166 $3,443
Latanoprost Generic 216 $2,385
Timolol Maleate Generic 97 $1,440
Bromfenac Sodium Generic 12 $1,319
Difluprednate Generic 11 $1,194
Travoprost Generic 14 $1,188
Acetazolamide Generic 29 $900

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$5,088,071

Of which drugs: $4,417,434

Medicare patients

1,048

Average age 81

Services billed

108,772

663 women, 385 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 33%
Chronic kidney disease 32%
Ischemic heart disease 26%
Atrial fibrillation 25%
Heart failure 22%
Depression 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, faricimab-svoa, 0.1 mg J2777 Office 281 90,840 $2,491,014
Injection, aflibercept, 1 mg J0178 Office 191 1,532 $996,288
Injection, pegcetacoplan, intravitreal, 1 mg J2781 Office 73 4,890 $569,532
Injection, aflibercept hd, 1 mg J0177 Office 46 1,048 $276,574
Injection, bevacizumab, 10 mg J9035 Office 349 1,307 $71,657
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 17 282 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
  • Pacira Pharmaceuticals Incorporated $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

4 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record